Systematic review and meta-analysis of the effect of probiotic supplementation on functional constipation in children

Lei Jin, MSa,*, Lin Deng, MSb, Wei Wu, MSc, Zhenyi Wang, BSc, Wanjin Shao, BSc, Jianhua Liu, MSd

Abstract

Background: To evaluate the effect of probiotic supplementation on functional constipation in children.

Methods: We performed electronic searches in PubMed, Embase, and Cochrane Library without language restriction to identify relevant studies from the time of inception of these databases to March 2018. The relative risk or weighted mean difference was calculated to evaluate the treatment effect of probiotics using random-effects model.

Results: We included 4 trials reporting data on 382 children with functional constipation. Overall, there were no significant differences in treatment success (P = .697), spontaneous bowel movements per week (P = .571), fecal soiling episodes per week (P = .642), straining at defecation (P = .408), use of lactulose (P = .238), use of laxatives (P = .190), fecal incontinence (P = .139), pain during defecation (P = .410), flatulence (P = .109), and adverse events (P = .979) between probiotics and placebo. Further, the use of probiotics was associated with lower frequency of glycerin enema use (weighted mean difference -2.40, P = .004) and abdominal pain (weighted mean difference -4.80, P < .001).

Conclusion: The findings of this study suggested that the use of probiotics was associated with significant improvement in glycerin enema use and abdominal pain but did not affect the treatment success and other function indices.

Abbreviations: CIs = confidence intervals, RCTs = randomized controlled trials, RRIs = relative risks, sBMs = spontaneous bowel movements, sWMDS = weighted mean differences.

Keywords: childhood, functional constipation, meta-analysis, probiotics, systematic review

1. Introduction

Chronic constipation is a common problem in the pediatric population and is characterized by infrequent painful defecation, fecal incontinence, and abdominal pain. The reported prevalence rate of chronic constipation in the Western world is 3% but is 10% to 25% in children referred to pediatric gastroenterologists.[1–3] Chronic constipation is associated with pain and no identifiable organic cause in more than 90% of children and is usually of functional origin.[4,5] The goals of treatment for chronic constipation are to achieve remission in fecal impaction, improve bowel habits, and promote passing of soft stools without discomfort.

Lactulose, an osmotic laxative, is currently widely used to manage constipation in children, although it does not significantly relieve symptoms and requires additional treatment strategy in children with functional constipation.[6] Previous studies have suggested that probiotic supplementation could treat or prevent multiple gastrointestinal disorders.[7,8] Potential mechanisms of probiotics are as follows: probiotics could adhere to the intestinal epithelia, inhibiting pathogenic organisms;[9] they could exert inflammatory effects in the gastrointestinal lumen;[10] and they could convert undigested carbohydrates into short-chain fatty acids, improving gut function.

Several studies have reported the effect of probiotics on childhood functional gastrointestinal disorders and showed that probiotic use was associated with a significant improvement in symptoms in patients with abdominal pain-related functional gastrointestinal disorders, especially in patients with irritable bowel syndrome.[11–20] However, data on the effect of probiotics on functional constipation in children are both limited and inconclusive. Therefore, we performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the effect of probiotic supplementation on functional constipation in children.

2. Methods

2.1. Data sources, search strategy, and selection criteria

This review was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses statement issued in 2009 (Appendix 1, http://links.lww.com/MD/C494).[21] We performed a systematic review and meta-analysis to identify trials on probiotics for children with functional constipation that were published until March 2018. For literature review, we searched PubMed, Embase, and Cochrane Library using the following core terms: “probiotic” AND “constipation.” The details of search strategy for each database are presented in Appendix 2, http://links.lww.com/MD/C494. The inclusion criteria were limited to RCTs. We also conducted manual searches of the reference lists from all relevant original and review articles to identify additional eligible studies. No language restriction was applied. Unpublished trials were excluded. The medical subject heading, methods, participants’ status, study design, intervention, and outcome variables were used to identify relevant studies.

The literature search was independently performed by 2 reviewers using a standardized approach. Any inconsistencies were settled by group discussion until a consensus was reached. The following studies were included in the analysis: RCTs; studies that included patients with functional constipation, which was defined based on clinical symptoms, physician’s opinion, or the Rome I, II, or III criteria; studies that included patients with a mean age of <6.0 years; studies in which the intervention group received probiotics, whereas the control group received placebo; and studies in which the primary outcome was treatment success, which was defined as ≥3 spontaneous bowel movements (sBMs) per week with no fecal soiling, and the secondary outcomes were sBMs per week, fecal soiling episodes per week, straining and pain during defecation, use of lactulose, glycerin enema, and laxatives, abdominal pain, fecal incontinence, flatulence, and adverse events.

2.2. Data collection and quality assessment

The collected data included the first author’s name, publication year, country, sample size, sex ratio, mean age, duration of constipation, diagnostic criteria, intervention, control, reported endpoints, and study design variables. The reviewers independently scanned the titles and abstracts of the studies for eligibility and relevance. Potentially relevant articles were retrieved and reviewed for selection based on the inclusion and exclusion criteria. Any discrepancies were resolved by discussion. Two reviewers independently assessed the quality of studies using the Jadad scale, which assesses the reporting of essential points in an RCT (i.e., randomization, blinding, withdrawals, and dropouts).[22] The 3-point questionnaire produces a total score ranging from 0 to 5. In case of a disagreement, a consensus was reached through discussion.

2.3. Statistical analysis

Relative risks (RRs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs) were calculated using the outcomes extracted from each study before data pooling. We used a random-effects model for pooled RRs or WMDs with 95% CI to evaluate the treatment effect of probiotics.[23,24] We also performed a sensitivity analysis for treatment success by removing each individual study from the meta-analysis.[25] Subgroup analyses were planned to explore potential sources of heterogeneity but were not performed because of the small number of trials finally identified. Heterogeneity among trials was investigated using the Q statistic and P values <.10 were indicative of significant heterogeneity.[26,27] We evaluated potential publication bias using funnel plots. The Egger[28] and Begg tests[29] were also used to statistically assess publication bias for treatment success. All reported P values were 2-sided, and P values <.05 were considered statistically significant. Statistical analyses were performed using Stata 10 software (StataCorp, College Station, TX).

3. Results

The results of the study selection process are shown in Fig. 1. A total of 980 potentially relevant articles were identified after a systematic search in electronic databases, professional journals, and other sources. After reviewing the titles or abstracts, 919 articles were excluded as they did not meet the inclusion criteria, leaving 61 articles for further full-text review. After full-text review, 57 studies were discarded, and 4 trials were finally identified and included in the analysis of efficacy and safety of probiotics in children with functional constipation.[30] The remaining studies were excluded because they were reported as conference abstracts without full text, were performed on similar populations, evaluated adult patients, had non-RCT study designs, or included patients with other diseases. A manual search of the reference lists from the articles of these trials did not yield any new eligible studies. The general characteristics of the included trials are presented in Table 1.

The sample sizes of the trials varied from 45 to 159 children with functional constipation. Of the trials, 2 were conducted in Poland[30–33] 1 in the Netherlands and Poland,[32] and the remaining one in China.[31] The mean age of the included children ranged from 34.6 to 81.0 months, and the duration of constipation ranged from 14.3 to 40.8 months. Two of the included trials defined constipation as <3 sBMs per week for at least 2 months or 12 weeks,[30,31] whereas the remaining 2 trials defined it according to the Rome III criteria.[32,33] All included trials were of high study quality, as assessed using the Jadad scale. Overall, 3 trials had a score of 5,[30,32,33] whereas the remaining one trial had a score of 4.[31]

After pooling all included trials, we noted that probiotics have no significant effect on treatment success rate compared with placebo (RR 1.05, 95% CI 0.81–1.38, P = .697; Fig. 2), but potential evidence of significant heterogeneity was observed. A sensitivity analysis for treatment success was consequently performed, and after each study was sequentially excluded from the pooled analysis, the conclusion was not affected by the exclusion of any specific study (Table 2). Finally, we examined the funnel plots, which indicated no significant publication bias for treatment success (Fig. 3).

The summary results for other outcomes are presented in Table 3. The pooled analysis showed that children who received probiotics had lower frequency of glycerin enema use (WMD –2.40, 95% CI –4.03 to –0.77, P = .004) and abdominal pain (WMD –4.80, 95% CI –7.08 to –2.52, P < .001). However, probiotics had no significant effect on sBMs per week (WMD 0.89, 95% CI –2.18 to 3.95, P = .571), fecal soiling episodes per week (WMD 0.15, 95% CI –0.48 to 0.79, P = .642), straining during defecation (WMD –0.30, 95% CI –1.01 to 0.41, P = .408), use of lactulose (WMD –1.80, 95% CI –4.79 to 1.19, P = .238), use of laxatives (RR 0.72, 95% CI 0.44–1.18, P = .190), fecal incontinence (RR 0.75, 95% CI 0.51–1.10, P = .139), pain during defecation (RR 1.16, 95% CI 0.81–1.66, P = .410), flatulence (RR 0.65, 95% CI 0.39–1.10, P = .109), and adverse events (RR 1.01, 95% CI 0.62–1.63, P = .979).
Potential articles from PubMed, EmBase and the Cochrane (n=980)

Abstracts and title excluded during first screening (n=919)

Articles reviewed in details (n=61)

Articles excluded (n=57)
Other design (n=18)
Conference abstracts (n=11)
Study reported same populations (n=11)
Patients with other disease (n=13)
Included adult patients (n=4)

4 trials included in meta-analysis

---

**Figure 1.** Flow diagram of the literature search and trial selection process.

---

**Table 1**

Demographic characteristics of included studies.

| Study                          | Publication year | Country       | Sample size | Sex ratio (M/F) | Mean age (mo) | Duration of constipation (mo) | Diagnostic criteria | Intervention | Control | Jadad score |
|-------------------------------|------------------|---------------|-------------|-----------------|---------------|-----------------------------|---------------------|--------------|----------|-------------|
| Banaszkiewicz and Szajewska   | 2005             | Poland        | 84          | NA              | 72.2          | 23.5                        | Defined as: stools <3 sBM/wk for at least 12 wk | 1 mL/kg/d of 70% lactulose plus 10^9 CFU of LGG Lcr35 (8 x 10^9) CFU/d | 1 mL/kg/d of 70% lactulose plus placebo MgO (50 mg/kg/d) or placebo | 5          |
| Bu et al                      | 2007             | China         | 45          | 23/22           | 34.6          | 21.7                        | Defined as: stools <3 sBM/wk for at least 2 mo, and anal fissures or soiling or hard/large stools | Biﬁdobacterium lactis strain DN-173 010 4.25 x 10^9 CFU | Nonfermented dairy product (125-g pot) without probiotics and with a low content of lactose (<2.5 g per pot) | 4          |
| Tabbers et al                 | 2011             | Netherlands and Poland | 159        | 83/76           | 81.0          | 40.8                        | Rome III criteria | Biﬁdobacterium lactis strain DN-173 010 4.25 x 10^9 CFU | Placebo | 5          |
| Wołyniak et al                | 2017             | Poland        | 94          | 42/52           | 38.0          | 14.3                        | Rome III criteria | Lcr35 (8 x 10^9) CFU/d | Placebo | 5          |

CFU= colony-forming units, Lcr35 = Lactobacillus casei rhamnosus, LGG = Lactobacillus rhamnosus GG, MgO = magnesium oxide, sBM = spontaneous bowel movements.
4. Discussion

The present meta-analysis aimed to evaluate the efficacy of probiotics in children with functional constipation. Four trials that included 382 patients were identified. The results showed that probiotic supplementation resulted in lower frequency of glycerin enema use and abdominal pain but had no significant effect on other outcomes. These results may help better clarify the efficacy of probiotics in children with functional constipation and can aid physicians in selecting appropriate treatment strategies.

A previous meta-analysis suggested that the use of probiotics was associated with increased treatment success rate but had no significant effect on the frequency of abdominal pain. Further, the summary results did not indicate a significant improvement in stool patterns. The inherent limitation of the previous meta-analysis is that the effect of probiotics on functional constipation was not evaluated. Moreover, many other outcomes were not reported. Dimidi et al. conducted a meta-analysis of RCTs on the effect of probiotics on functional constipation in adults and found that probiotics could improve whole gut transit time, stool frequency, and stool consistency. However, the treatment effect of probiotics in children remains unclear. Therefore, we conducted a comprehensive systematic review and meta-analysis to evaluate the efficacy and safety of probiotics in children with functional constipation.

There was no significant difference in treatment success rate between probiotics and placebo. Majority of the included studies reported the nonsignificant effect of probiotics on treatment success, except for the trial performed by Bu et al. They reported that Lactobacillus casei rhamnosus was associated with a reduced treatment success rate compared with placebo, with no significant difference between Lactobacillus casei rhamnosus and magnesium oxide. Further, they suggested that Lactobacillus casei rhamnosus was associated with a reduced frequency of abdominal pain. Banaszkiewicz and Szajewska reported that the treatment success rate was 68% and 65% in the Lactobacillus GG group and 72% and 64% in the placebo group at 12 and 24 weeks, respectively, and that there were no significant differences in sBMs per week, fecal soiling episodes per week, adverse events, and overall tolerance between both groups at 4, 8, and 12 weeks. Tabbers et al. indicated that both fermented dairy product containing Bifidobacterium lactis DN-173010 and control product could improve stool frequency from baseline to after 3 weeks, with no significant difference between both, and that no serious adverse events were observed in constipated children. Finally, Wojtyniak et al. suggested that Lactobacillus casei rhamnosus was not associated with significant improvement in symptoms in children with functional constipation aged less than 5 years and did not recommend the use of probiotics in children with functional constipation.

The findings of this study suggested that probiotic supplementation led to significant persistent improvement in glycerin enema use and abdominal pain. However, probiotics were not associated with several important indices. This could be because most trials were designed with other outcomes as the primary

| Excluding study | RR and 95% CI | P value | Heterogeneity (%) | P value for heterogeneity |
|-----------------|---------------|---------|-------------------|--------------------------|
| Banaszkiewicz and Szajewska | 1.10 (0.69–1.75) | .688 | 71.1 | .032 |
| Bu et al | 1.03 (0.87–1.22) | .707 | 14.3 | .311 |
| Tabbers et al | 1.06 (0.66–1.70) | .811 | 68.3 | .043 |
| Wojtyniak et al | 1.16 (0.83–1.62) | .574 | 56.6 | .100 |

Figure 2. Effect of probiotics on treatment success.
endpoint and because their sample sizes were too small to detect potentially clinically relevant differences. Further, the few trials that reported these outcomes showed no statistically significant differences. Therefore, we simply reported a relative result and provided a synthetic and comprehensive review.

The strengths of our study should be highlighted. First, the large sample size allowed us to quantitatively assess the efficacy of probiotics in children with functional constipation; thus, our findings are potentially more robust than those of any individual study. Second, the study reported children with functional constipation, and no such meta-analysis has been previously performed. Third, the summary results for sBMs per week, fecal soiling episodes per week, straining and pain during defecation, use of lactulose, glycerin enema, and laxatives, abdominal pain, fecal incontinence, flatulence, and adverse events were presented.

The limitations of our study are as follows: Publication bias was inevitable because this meta-analysis was based on published studies, which might overestimate the treatment effects of probiotics. Subgroup analysis was not performed as a small number of trials were included. The meta-analysis used pooled data (individual data were not available), which prevented a detailed analysis to obtain more comprehensive results.

Table 3
The summary results of all evaluated outcomes.

| Outcomes                        | RR or WMD and 95% CI | P value | Heterogeneity (%) | P value for heterogeneity |
|---------------------------------|----------------------|---------|-------------------|--------------------------|
| sBMs per week                   | 0.89 (0.62 to 1.22)  | .571    | 95.0              | <.001                     |
| Fecal soiling episodes per week | 0.85 (0.75 to 0.96)  | .642    | 62.4              | .103                      |
| Straining at defecation         | 0.30 (0.20 to 0.45)  | .408    | —                 | —                         |
| Use of lactulose                | 1.80 (0.93 to 3.47)  | .238    | —                 | —                         |
| Use of glycerin enema           | 2.40 (1.63 to 3.54)  | .004    | —                 | —                         |
| Abdominal pain                  | 4.80 (3.08 to 7.23)  | <.001   | 62.0              | .620                      |
| Patients using laxatives        | 0.72 (0.44–1.18)     | .190    | 0.0               | .820                      |
| Fecal incontinence              | 0.75 (0.51–1.11)     | .130    | —                 | —                         |
| Pain during defecation          | 1.16 (0.81–1.66)     | .410    | —                 | —                         |
| Flatulence                      | 0.65 (0.39–1.10)     | .109    | —                 | —                         |
| Adverse events                  | 1.01 (0.62–1.63)     | .979    | —                 | —                         |
5. Conclusion
The results of this study suggested that probiotic supplementation might result in reduced frequency of glycerin enema use and abdominal pain but has no significant effect on treatment success. Stool BMs per week, fecal soiling episodes per week, straining, and pain during defecation, use of lactulose and laxatives were not significantly different between the probiotic group and the placebo group. Future studies should focus on specific types of probiotics and children with specific characteristics.

Author contributions
Conceptualization: Lei Jin.
Formal analysis: Lei Jin.
Investigation: Lin Deng, Wei Wu, Jianhua Liu.
Project administration: Lei Jin.
Resources: Wanjin Shao, Jianhua Liu.
Software: Zhenyi Wang.
Supervision: Wei Wu.
Validation: Lin Deng, Zhenyi Wang.
Visualization: Wanjin Shao.
Writing – original draft: Lei Jin.
Writing – review & editing: Lei Jin.

References
[1] van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. Am J Gastroenterol 2006;101:2401–9.
[2] Benninga MA, Voskuil WP, Tamuinia JA. Childhood constipation: is there new light in the tunnel? J Pediatr Gastroenterol Nutr 2004;39:484–64.
[3] Chitkara DK, Rawat DJ, Talley NJ. The epidemiology of childhood recurrent abdominal pain in Western countries: a systematic review. Am J Gastroenterol 2005;100:1868–75.
[4] American Academy of Pediatrics Subcommittee on Chronic Abdominal Pain; North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Chronic abdominal pain in children. Pediatrics 2005;115:e370–81.
[5] Di Lorenzo C, Colletti RB, Lehmann HP, et al. Chronic abdominal pain in children: a technical report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005;40:249–61.
[6] Baker SS, Liptak GS, Colletti RB, et al. Constipation in infants and children: evaluation and treatment. A medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 1999;29:612–26.
[7] Brown AC, Valere A. Probiotics and medical nutrition therapy. Nutr Clin Care 2004;7:56–68.
[8] Lemberg DA, Oau CY, Day AS. Probiotics in paediatric gastrointestinal diseases. J Paediatr Child Health 2007;43:331–6.
[9] Silva M, Jacobus NV, Deneke C, et al. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother 1987;31:1231–3.
[10] O’Mahony L, Mccarthy J, Kelly P, et al. Lactobacillus and bifidobacteria in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541–51.
[11] Weizman Z, Abu-Abed J, Binszok M. Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in children: a randomized, double-blind, placebo-controlled trial. J Pediatr 2016;174:160.e1–4.e1.
[12] Jadresin O, Hojsak I, Minak Z, et al. Lactobacillus reuteri DSM 17938 in the treatment of functional abdominal pain in children: RCT study. J Pediatr Gastroenterol Nutr 2017;64:925–9.
[13] Beigrup LM, de Muckadell OB, Kjeldsen J, et al. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome—a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 2013;48:1127–35.
[14] Eftekhar K, Vahedi Z, Kamali Aghdam M, et al. A randomized double-blind placebo-controlled trial of Lactobacillus reuteri for chronic functional abdominal pain in children. Iran J Pediatr 2015;25:e2616.
[15] Maragkoudaki M, Choularas G, Orel R, et al. Lactobacillus reuteri DSM 17938 and a placebo both significantly reduced symptoms in children with functional abdominal pain. Acta Paediatr 2017;106:1857–62.
[16] Rauerson M, Michael S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 2005;147:197–201.
[17] Francavilla R, Minnelli V, Magista AM, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics 2010;126:e1445–52.
[18] Guandalini S, Magazzu G, Chiara A, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 2010;51:24–30.
[19] Gawrońska A, Dziochczarz P, Horvath A, et al. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007;25:777–84.
[20] Romano C, Ferrau V, Cavataio F, et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health 2014;50:E68–71.
[21] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
[22] Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–2.
[23] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
[24] Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making 2005;25:646–54.
[25] Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 1999;8:726–9.
[26] Deeks JJ, Higgins JPT, DG. A. Analyzing data and undertaking meta-analyses. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1. Oxford, UK: The Cochrane Collaboration; 2008:chap 9.
[27] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
[28] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
[29] Pegu CR, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.
[30] Tabbers MM, Chmielewska A, Roseboom MG, et al. Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics 2011;127:e1392–9.
[31] Bu LN, Chang MH, Ni YH, et al. Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation. Pediatr Int 2007;49:485–90.
[32] Tabbers MM, Chmielewska A, Roseboom MG, et al. Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics 2011;127:e1392–9.
[33] Wojtyniak K, Horvath A, Dzieczciarz P, et al. Lactobacillus casei rhamnosus Lcr35 in the management of functional constipation in children: a randomized trial. J Pediatr 2017;184:101–3.
[34] Korterink JJ, Ockeloen L, Benninga MA, et al. Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis. Acta Paediatr 2014;103:365–72.
[35] Dimidi E, Christodoulides S, Fragkos KC, et al. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014;100:1075–84.